RU2007118420A - ПРИМЕНЕНИЕ 4-(4-МЕТИЛПИПЕРАЗИН-1-ИЛМЕТИЛ)-N-[4-МЕТИЛ-3-(ПИРИДИН-3-ИЛ)-2-ИЛАМИНО)ФЕНИЛ]БЕНЗАМИДА ДЛЯ ИНГИБИРОВАНИЯ РЕЦЕПТОРНОЙ ТИРОЗИНКИНАЗЫ с-fms - Google Patents
ПРИМЕНЕНИЕ 4-(4-МЕТИЛПИПЕРАЗИН-1-ИЛМЕТИЛ)-N-[4-МЕТИЛ-3-(ПИРИДИН-3-ИЛ)-2-ИЛАМИНО)ФЕНИЛ]БЕНЗАМИДА ДЛЯ ИНГИБИРОВАНИЯ РЕЦЕПТОРНОЙ ТИРОЗИНКИНАЗЫ с-fms Download PDFInfo
- Publication number
- RU2007118420A RU2007118420A RU2007118420/15A RU2007118420A RU2007118420A RU 2007118420 A RU2007118420 A RU 2007118420A RU 2007118420/15 A RU2007118420/15 A RU 2007118420/15A RU 2007118420 A RU2007118420 A RU 2007118420A RU 2007118420 A RU2007118420 A RU 2007118420A
- Authority
- RU
- Russia
- Prior art keywords
- methylpiperazin
- benzamide
- pyridin
- phenyl
- methyl
- Prior art date
Links
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 title claims abstract 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 230000002025 microglial effect Effects 0.000 claims abstract 4
- 208000006332 Choriocarcinoma Diseases 0.000 claims abstract 3
- 206010014733 Endometrial cancer Diseases 0.000 claims abstract 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims abstract 3
- 208000002291 Histiocytic Sarcoma Diseases 0.000 claims abstract 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract 3
- 201000003914 endometrial carcinoma Diseases 0.000 claims abstract 3
- 201000008825 fibrosarcoma of bone Diseases 0.000 claims abstract 3
- 201000006812 malignant histiocytosis Diseases 0.000 claims abstract 3
- 201000000306 sarcoidosis Diseases 0.000 claims abstract 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 230000002518 glial effect Effects 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000001608 teratocarcinoma Diseases 0.000 claims 2
- -1 4-methylpiperazin-1-ylmethyl Chemical group 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 5
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 3
- 229960002411 imatinib Drugs 0.000 abstract 3
- 201000009051 Embryonal Carcinoma Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 229940080856 gleevec Drugs 0.000 abstract 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (4)
1. Применение 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-(пиридин-3-ил)пиримидин-2-иламино)фенил]бензамида (соединение I) для получения лекарственного средства, предназначенного для лечения связанных с киназой с-fms заболеваний, которые выбирают из группы, включающей хориокарциному, злокачественный гистиоцитоз, тератокарциному, карциному эндометрия, микроглиальные опухоли мозга, саркоидоз, болезнь Крейцфельда-Якоба и ее варианты, в развитии которых принимают участие глиальные макрофаги, или боковой амиотрофический склероз.
2. Применение по п.1, в котором соединением I является его монометансульфонат.
3. Коммерческая упаковка, включающая соединение I или его фармацевтичеки приемлемую соль и инструкции по применению по п.1 или 2.
4. Способ лечения теплокровного животного, предпочтительно человека, страдающего или предположительно страдающего от связанного с киназой c-fms заболевания, которое выбирают из группы, включающей хориокарциному, злокачественный гистиоцитоз, тератокарциному, карциному эндометрия, микроглиальные опухоли мозга, саркоидоз, болезнь Крейцфельда-Якоба и ее варианты, в развитии которых принимают участие глиальные макрофаги, или боковой амиотрофический склероз, причем указанный способ включает введение указанному животному пригодного количества соединения I.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61974404P | 2004-10-18 | 2004-10-18 | |
| US60/619,744 | 2004-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007118420A true RU2007118420A (ru) | 2008-11-27 |
Family
ID=36202610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007118420/15A RU2007118420A (ru) | 2004-10-18 | 2005-10-17 | ПРИМЕНЕНИЕ 4-(4-МЕТИЛПИПЕРАЗИН-1-ИЛМЕТИЛ)-N-[4-МЕТИЛ-3-(ПИРИДИН-3-ИЛ)-2-ИЛАМИНО)ФЕНИЛ]БЕНЗАМИДА ДЛЯ ИНГИБИРОВАНИЯ РЕЦЕПТОРНОЙ ТИРОЗИНКИНАЗЫ с-fms |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20080255139A1 (ru) |
| EP (1) | EP1804800B1 (ru) |
| JP (1) | JP2008516898A (ru) |
| KR (1) | KR20070083705A (ru) |
| CN (1) | CN101035535A (ru) |
| AT (1) | ATE492277T1 (ru) |
| AU (1) | AU2005297321A1 (ru) |
| BR (1) | BRPI0517083A (ru) |
| CA (1) | CA2580976A1 (ru) |
| DE (1) | DE602005025514D1 (ru) |
| IL (1) | IL182419A0 (ru) |
| MA (1) | MA28946B1 (ru) |
| MX (1) | MX2007004660A (ru) |
| NO (1) | NO20072501L (ru) |
| NZ (1) | NZ554009A (ru) |
| RU (1) | RU2007118420A (ru) |
| TN (1) | TNSN07141A1 (ru) |
| WO (1) | WO2006042362A1 (ru) |
| ZA (1) | ZA200702316B (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2215482A2 (en) * | 2007-10-31 | 2010-08-11 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
| US20180000771A1 (en) * | 2015-01-13 | 2018-01-04 | Kyoto University | Agent for preventing and/or treating amyotrophic lateral sclerosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837237A (en) * | 1985-07-09 | 1989-06-06 | Fred Hutchinson Cancer Research Center | Therapy using glucosidase processing inhibitors |
| CA2446939C (en) * | 2001-05-16 | 2005-08-02 | Matthias Stein-Gerlach | Pyridylpyrimidine derivatives as effective compounds against prion diseases |
| US20060052387A1 (en) * | 2002-06-26 | 2006-03-09 | Marsh Clay B | Organic compounds |
-
2005
- 2005-10-17 RU RU2007118420/15A patent/RU2007118420A/ru unknown
- 2005-10-17 KR KR1020077008716A patent/KR20070083705A/ko not_active Ceased
- 2005-10-17 US US11/576,967 patent/US20080255139A1/en not_active Abandoned
- 2005-10-17 BR BRPI0517083-4A patent/BRPI0517083A/pt not_active IP Right Cessation
- 2005-10-17 CA CA002580976A patent/CA2580976A1/en not_active Abandoned
- 2005-10-17 EP EP05793868A patent/EP1804800B1/en not_active Expired - Lifetime
- 2005-10-17 AT AT05793868T patent/ATE492277T1/de not_active IP Right Cessation
- 2005-10-17 AU AU2005297321A patent/AU2005297321A1/en not_active Abandoned
- 2005-10-17 NZ NZ554009A patent/NZ554009A/en not_active IP Right Cessation
- 2005-10-17 WO PCT/AU2005/001602 patent/WO2006042362A1/en not_active Ceased
- 2005-10-17 JP JP2007535954A patent/JP2008516898A/ja active Pending
- 2005-10-17 DE DE602005025514T patent/DE602005025514D1/de not_active Expired - Lifetime
- 2005-10-17 CN CNA2005800338341A patent/CN101035535A/zh active Pending
- 2005-10-17 MX MX2007004660A patent/MX2007004660A/es unknown
-
2007
- 2007-03-20 ZA ZA200702316A patent/ZA200702316B/xx unknown
- 2007-04-10 IL IL182419A patent/IL182419A0/en unknown
- 2007-04-17 TN TNP2007000141A patent/TNSN07141A1/fr unknown
- 2007-04-25 MA MA29848A patent/MA28946B1/fr unknown
- 2007-05-15 NO NO20072501A patent/NO20072501L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006042362A1 (en) | 2006-04-27 |
| IL182419A0 (en) | 2007-09-20 |
| KR20070083705A (ko) | 2007-08-24 |
| MA28946B1 (fr) | 2007-10-01 |
| EP1804800A1 (en) | 2007-07-11 |
| EP1804800A4 (en) | 2008-03-19 |
| DE602005025514D1 (de) | 2011-02-03 |
| CN101035535A (zh) | 2007-09-12 |
| CA2580976A1 (en) | 2006-04-27 |
| MX2007004660A (es) | 2007-10-17 |
| EP1804800B1 (en) | 2010-12-22 |
| ZA200702316B (en) | 2008-09-25 |
| AU2005297321A1 (en) | 2006-04-27 |
| NO20072501L (no) | 2007-05-15 |
| US20080255139A1 (en) | 2008-10-16 |
| ATE492277T1 (de) | 2011-01-15 |
| BRPI0517083A (pt) | 2008-09-30 |
| TNSN07141A1 (en) | 2008-11-21 |
| NZ554009A (en) | 2010-09-30 |
| JP2008516898A (ja) | 2008-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6362623B2 (ja) | ナトリウムチャネルの調節剤としてのキノリンおよびキノキサリンアミド | |
| MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| HRP20050318A2 (en) | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflamatory, ischaemic and remodelling processes | |
| MA49952B1 (fr) | Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations | |
| DK1651615T3 (da) | Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander | |
| DE60118430D1 (de) | Behandlung gastrointestinaler stroma-tumoren | |
| EA201070164A1 (ru) | Твердый препарат, включающий алоглиптин и гидрохлорид метформина | |
| RU2008108898A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| DK1735278T3 (da) | Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser | |
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| RU2008135690A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| EA201070366A1 (ru) | 3-метил-2-((2s)-2-(4-(3-метил-1,2,4-оксадиазол-5-ил)фенил)морфолино)-6-(пиримидин-4-ил)пиримидин-4(3н)-он в качестве ингибитора тау-протеинкиназы | |
| TW200800946A (en) | Substituted piperazines as metabotropic glutamate receptor antagonists | |
| EA200600829A1 (ru) | Новые кристаллические формы {2-[1-(3,5-бистрифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]-пиридин-3-ил}-(2-хлорфенил)метанона | |
| RU2011105059A (ru) | Применение производных пиримидиламинобензамида для лечения фиброза | |
| MY146403A (en) | F, g, h, i and k crystal forms of imatinib mesylate | |
| EP1817311A4 (en) | 2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS AS BETA SEKTRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| RU2007118420A (ru) | ПРИМЕНЕНИЕ 4-(4-МЕТИЛПИПЕРАЗИН-1-ИЛМЕТИЛ)-N-[4-МЕТИЛ-3-(ПИРИДИН-3-ИЛ)-2-ИЛАМИНО)ФЕНИЛ]БЕНЗАМИДА ДЛЯ ИНГИБИРОВАНИЯ РЕЦЕПТОРНОЙ ТИРОЗИНКИНАЗЫ с-fms | |
| JP2008516959A5 (ru) | ||
| MX2007000576A (es) | Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias. | |
| RU2019113752A (ru) | Композиции апилимода и способы их применения при лечении болезни альцгеймера | |
| ATE524171T1 (de) | Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit | |
| HRP20100265T1 (hr) | Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti |